Novartis: Renal Insufficiency trials

The registry lists 37 Renal Insufficiency studies with Novartis as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 23Phase 2 8Phase 3 6Phase 4 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal FunctionRecruitingNCT07797322Phase 1
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart FailureTerminatedNCT03152552Phase 2Results posted
• Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.CompletedNCT03131479Phase 2Results posted
• Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) PatientsTerminatedNCT02064868Phase 3Results posted
• Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) PatientsCompletedNCT02002702Phase 2Results posted
• Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)CompletedNCT01950819Phase 4Results posted
• Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal DysfunctionCompletedNCT01593787Phase 3Results posted
• Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal FunctionCompletedNCT01569815Phase 1Results posted
• A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.CompletedNCT07032272Phase 1
• Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionActive, not recruitingNCT06004661Phase 2
• Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy ParticipantsWithdrawnNCT05541159Phase 1
• Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy VolunteersCompletedNCT03605277Phase 1
• A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)CompletedNCT03159416Phase 1
• Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy SubjectsCompletedNCT03087942Phase 1
• Pharmacokinetics of Dabrafenib in Subjects With Renal ImpairmentCompletedNCT02852239Phase 1
• Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011CompletedNCT02431481Phase 1
• A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal FunctionCompletedNCT02399202Phase 1
• Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.CompletedNCT02048787Phase 1
• The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal InsufficiencyCompletedNCT02020434Phase 1
• A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal FunctionCompletedNCT01904214Phase 1
• PK of Serelaxin in Severe Renal Impairment and ESRDCompletedNCT01875523Phase 1
• An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal DysfunctionCompletedNCT01846468Phase 1
• Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy SubjectsCompletedNCT01660295Phase 1/2
• Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal ImpairmentCompletedNCT01613690Phase 1
• Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney DiseaseWithdrawnNCT01593527Phase 3
• A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy VolunteersCompletedNCT01578928Phase 1
• Pharmacokinetics of LCQ908 in Patients With Renal ImpairmentCompletedNCT01558323Phase 1
• Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy SubjectsCompletedNCT01459250Phase 1
• An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy SubjectsCompletedNCT01442259Phase 1
• Real-world Aliskiren Use in Diabetic PatientsCompletedNCT01393860
• Study in Patients With Untreated Multiple Myeloma and Renal InsufficiencyCompletedNCT01337752Phase 2
• Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired PatientsCompletedNCT00818571Phase 1/2
• Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)CompletedNCT00770081Phase 3
• Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)CompletedNCT00765830Phase 3
• Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.CompletedNCT00731523Phase 1
• Efficacy and Safety of Relaxin for the Treatment of Acute Heart FailureCompletedNCT00520806Phase 2/3
• Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone MetastasesCompletedNCT00434447Phase 4